Neumora Therapeutics (NMRA) Depreciation & Amortization (CF) (2022 - 2026)

Neumora Therapeutics' Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $8000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 94.9% year-over-year to $8000.0 in Q1 2026; TTM through Mar 2026 was $59000.0, a 90.63% decrease from a year earlier, with the FY2025 full-year figure at $208000.0, down 67.04% from the prior year.
• Depreciation & Amortization (CF) retreated to $8000.0 in Q1 2026 per NMRA's latest filing, from $9000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $198000.0 in Q4 2023 and bottomed at $8000.0 in Q1 2026.
• The 5-year median for Depreciation & Amortization (CF) is $157000.0 (2024), against an average of $121428.6.
• Across the five-year window, Depreciation & Amortization (CF) advanced 29.41% in 2023 and plunged 94.9% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $153000.0 in 2022, then increased by 29.41% to $198000.0 in 2023, then decreased by 20.71% to $157000.0 in 2024, then sank by 94.27% to $9000.0 in 2025, then decreased by 11.11% to $8000.0 in 2026.
• Per Business Quant, the three latest NMRA Depreciation & Amortization (CF) figures stand at $8000.0 (Q1 2026), $9000.0 (Q4 2025), and $23000.0 (Q3 2025).